首页 › 基金 › ORBIMED ADVISORS LLC › SVA

ORBIMED ADVISORS LLC 对 SVA 的持仓历史

Sinovac Biotech Ltd.

ORBIMED ADVISORS LLC 在 Q2 2026 的 13F 申报中披露持有 SVA(Sinovac Biotech Ltd.)2,718,735 股,市值约 US$184.5M,约占其申报组合的 3.71%,在其申报持仓中市值排名第 5 位。 ORBIMED ADVISORS LLC 最近 12 个申报季度中有 12 个季度披露了 SVA 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q2 2026)2.72M 股
申报持仓市值$184.47M
组合权重3.71%
首次申报Q3 2023
最近变动持有
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

ORBIMED ADVISORS LLC 对 SVA 的持仓演变

ORBIMED ADVISORS LLC 于 Q3 2023 首次披露 SVA 持仓:2,718,735 股(约 US$340.0M)。 在 12 次申报中,ORBIMED ADVISORS LLC 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 2,718,735 股、市值约 US$184.5M。

逐季持仓明细

季度股数金额变化
Q3 2023 2.72M $340.00M 新进
Q4 2023 2.72M $340.00M 持有
Q1 2024 2.72M $340.00M 持有
Q2 2024 2.72M $340.00M 持有
Q3 2024 2.72M $340.00M 持有
Q4 2024 2.72M $334.00M 持有
Q1 2025 2.72M $334.00M 持有
Q2 2025 2.72M $334.00M 持有
Q3 2025 2.72M $184.47M 持有
Q4 2025 2.72M $184.47M 持有
Q1 2026 2.72M $184.47M 持有
Q2 2026 2.72M $184.47M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 SVA 与 13F 数据

SVA(Sinovac Biotech Ltd.)的行业分类暂缺。我们追踪的基金中还有 8 只申报持有 SVA,申报仓位最大的包括:Vivo Capital, LLC (US$38.2M), Neumann Advisory Hong Kong Ltd (US$2.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 SVA 的基金

查看 SVA 的全部基金持有人 →

常见问题

How long has ORBIMED ADVISORS LLC held SVA?

ORBIMED ADVISORS LLC has disclosed SVA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in SVA?

As of Q2 2026, ORBIMED ADVISORS LLC holds 2.72M shares of SVA (Sinovac Biotech Ltd.), valued at $184.47M, representing 3.71% of its reported portfolio and ranking #5.

Has ORBIMED ADVISORS LLC been buying or selling SVA?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in SVA.

Which other funds hold SVA?

Other major institutional holders of SVA include Vivo Capital, LLC, Neumann Advisory Hong Kong Ltd, among 8 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.